Search research articles
Contact Us
Filters
Showing results (201-210 of 273) with videos related to
Page
of 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
February 9, 2025
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
D Ross Camidge, Shunichi Sugawara, Masashi Kondo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 3, 2022
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
British Journal of Cancer
|
January 4, 2023
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
Maria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
British Journal of Cancer
|
January 25, 2023
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
Maria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
The American Journal of Surgical Pathology
|
February 12, 2020
Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases
Yu Zhi Zhang, Cecilia Brambilla, Philip L Molyneaux, et al.
The Lancet. Oncology
|
May 19, 2022
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
Anna Minchom, Wei Yuan, Mateus Crespo, et al.
Page
of 28
Search research articles
Search
Showing results (201-210 of 273) with videos related to
Sort By:
Page
of 28
Lung Cancer (Amsterdam, Netherlands)
|
February 9, 2025
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
D Ross Camidge, Shunichi Sugawara, Masashi Kondo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 3, 2022
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
British Journal of Cancer
|
January 4, 2023
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
Maria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
British Journal of Cancer
|
January 25, 2023
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
Maria Antonietta Cerone, Tara C Mills, Rowena Sharpe, et al.
The American Journal of Surgical Pathology
|
February 12, 2020
Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases
Yu Zhi Zhang, Cecilia Brambilla, Philip L Molyneaux, et al.
The Lancet. Oncology
|
May 19, 2022
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
Anna Minchom, Wei Yuan, Mateus Crespo, et al.
Page
of 28